GlassScriptPhysician profile
Ronald P Markos
NPI 1851399786
$5,749.13
in general payments reported to CMS, 2019-2025
42 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $283 · 2021: $795 · 2022: $1,032 · 2023: $1,147 · 2024: $714 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780 · Education: $25.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.77 |
| Education | $25.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,827.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $538.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $509.86 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $405.64 | 2019-2025 | |
| Celgene Corporation | $291.70 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.04 | 2019-2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $141.47 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $132.06 | 2019-2023 | Injectafer |
| Gilead Sciences, INC. | $128.99 | 2020-2024 | |
| Ardelyx, INC. | $108.46 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $98.79 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $95.87 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $87.55 | 2021-2023 | |
| Lilly USA, LLC | $86.67 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $79.23 | 2019-2023 | Dificid, Zinplava |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Markos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.